Eloquest Healthcare and Omni-stat Medical Collaborate
Collaboration expands access to proven hemostatic technologies
Eloquest Healthcare, Inc. has announced an exciting partnership with Omni-stat Medical, Inc., both leaders in their fields. This strategic alliance aims to deliver innovative hemostatic solutions into acute care settings across the U.S., specifically targeting intensive care units and vascular access procedures. The partnership signifies an important step forward in improving patient outcomes during critical medical situations.
Significance of Hemostatic Technologies
Omni-stat Medical is known for its state-of-the-art hemostatic gauze products, which are essential in managing bleeding quickly and efficiently. These hemostatic solutions are crucial for clinicians who work under pressure, where every second counts, and the reliability of products can greatly affect patient outcomes. By incorporating Omni-stat’s technologies, Eloquest Healthcare strengthens its mission to advance clinical care and enhance vascular access management.
Leadership Perspectives
Tim O'Halla, President & CEO of Eloquest Healthcare, expressed enthusiasm about this collaboration, stating, "We are excited to partner with Omni-stat Medical to bring these proven hemostatic solutions into more hospitals and ICUs across the country. This agreement reflects our ongoing commitment to aligning with top-notch technologies that complement our offerings. Together, we can assist clinicians in elevating care and improving outcomes during some of the most challenging points in their treatment journey."
Omni-stat's Mission
On the other hand, Gina Milner, Director of US Commercial Operations at Omni-stat Medical, commented on the partnership's importance. "Omni-stat is proud to collaborate with Eloquest Healthcare. Their extensive expertise and respected presence in the acute care market makes them the perfect partner for promoting our hemostatic products. We are eager to work together to support clinicians with efficient solutions that significantly reduce blood loss and save critical time, ultimately enhancing patient safety and care quality."
About Eloquest Healthcare
Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. The company focuses on providing straightforward solutions that enhance clinical outcomes, improve care quality, decrease overall costs, and boost staff efficiency. Through innovative approaches, they aim to create a significant impact on patient care and health system efficiency.
About Omni-stat Medical
Omni-stat Medical is at the forefront of hemostatic technologies, dedicated to delivering rapid and effective solutions for the control of bleeding. Their product line is designed to accommodate varying levels of bleeding, from minor to severe, which allows healthcare providers to manage resources effectively and ensure better patient care outcomes. The commitment to innovation is central to Omni-stat’s mission in the healthcare field.
Frequently Asked Questions
What is the focus of the partnership between Eloquest and Omni-stat?
The partnership aims to promote hemostatic solutions in the U.S. acute care market, especially in intensive care units and vascular access procedures.
What products does Omni-stat Medical provide?
Omni-stat Medical provides proprietary hemostatic gauze products that quickly manage bleeding in critical care environments.
What does Eloquest Healthcare specialize in?
Eloquest Healthcare specializes in infection prevention and vascular access solutions, improving patient outcomes and enhancing clinical care standards.
Why is this partnership important for patient care?
This collaboration enhances the range of effective hemostatic products available, supporting clinicians in delivering timely and reliable care.
How do the companies plan to support clinicians?
Through the partnership, they aim to provide advanced hemostatic technologies that effectively reduce blood loss and improve patient safety and care outcomes.
